Jonathan Thompson, MD
Vascular Surgery · Omaha, NENPI 1831329689
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,531 of the $5,140 with a category attached, or 68.7%. 7 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 46.1% of the total. Reporting peaked in 2024 at $2,353 and has fallen 89.5% since, to $248 in 2025.
Across 47 payments — averaging $109.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$2K
- Medtronic$1K
- Silk Road Medical, Inc.$1K
- Cook Medical LLC$267
- Penumbra, Inc.$205
- Cvrx, Inc.$137
- plus $111 from 1 others
What the payments were for
- Speaking & faculty fees$2505%
- Travel & lodging$3,53169%
- Food & beverage$1,35926%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 27 | $2,372 |
| Medtronic | 8 | $1,043 |
| Silk Road Medical, Inc. | 6 | $1,006 |
| Cook Medical LLC | 2 | $267 |
| Penumbra, Inc. | 2 | $205 |
| Cvrx, Inc. | 1 | $137 |
| Reflow Medical Inc | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE TAG Thoracic Branch Endoprosthesis$1,379
- ENROUTE Transcarotid Neuroprotection System$897
- ENROUTE Transcarotid Stent System$897
- ENHANCE Transcarotid Peripheral Access Kit$897
- ENROUTE 0.014 Guidewire$897
- PIVOX Oblique Lateral Spinal System$814
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$572
- Indigo$212
- Barostim Neo System$137
How this compares
$5,140 in reported general payments places this provider in the 55th percentile of 35 vascular surgery providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 38 | $22,822 |
| EliquisApixaban | 21 | $12,882 |
| BrilintaTicagrelor | 17 | $10,954 |
| Cilostazol | 111 | $2,450 |
| Atorvastatin Calcium | 96 | $1,020 |
| ClopidogrelClopidogrel Bisulfate | 88 | $435 |
| Rosuvastatin Calcium | 36 | $223 |
| Gabapentin | 13 | $22 |
| Amlodipine Besylate | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Omaha
- John ParkOmaha$508K
- David VogelOmaha$41K
- Marcus BaltersOmaha$27K
- Anjan TalukdarOmaha$25K
- Iraklis PipinosOmaha$24K
- Rao GuttaOmaha$21K
- Tammy RamosOmaha$10K
- Yue GaoOmaha$9K
- Jason CookOmaha$7K
- Katherine BrownOmaha$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.